Last reviewed · How we verify

L-arginine + heme arginate

Radboud University Medical Center · FDA-approved active Small molecule

L-arginine and heme arginate work together to restore nitric oxide production and improve vascular function in patients with arginine deficiency or endothelial dysfunction.

L-arginine and heme arginate work together to restore nitric oxide production and improve vascular function in patients with arginine deficiency or endothelial dysfunction. Used for Sepsis-associated microvascular dysfunction, Arginine deficiency states, Endothelial dysfunction in critical illness.

At a glance

Generic nameL-arginine + heme arginate
SponsorRadboud University Medical Center
Drug classAmino acid supplement / Nitric oxide donor
TargetNitric oxide synthase (NOS); hemoglobin
ModalitySmall molecule
Therapeutic areaCardiovascular; Critical Care; Metabolic Disorders
PhaseFDA-approved

Mechanism of action

L-arginine is a semi-essential amino acid that serves as a substrate for nitric oxide synthase, enabling the production of nitric oxide, a critical vasodilator and signaling molecule. Heme arginate (also known as arginate heme) provides heme groups that support hemoglobin function and may enhance oxygen delivery. Together, these agents aim to restore endothelial function and improve microvascular perfusion in conditions characterized by arginine depletion or nitric oxide deficiency.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: